Jennifer Richer
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Triple Negative Breast Neoplasms | 14 | 2023 | 164 | 6.520 |
Why?
| Receptors, Androgen | 13 | 2023 | 136 | 5.620 |
Why?
| Breast Neoplasms | 43 | 2022 | 1994 | 4.240 |
Why?
| MicroRNAs | 17 | 2018 | 661 | 4.080 |
Why?
| Androgen Receptor Antagonists | 8 | 2021 | 32 | 2.690 |
Why?
| Anoikis | 7 | 2021 | 35 | 2.480 |
Why?
| Gene Expression Regulation, Neoplastic | 34 | 2021 | 1183 | 2.460 |
Why?
| Estrogen Receptor alpha | 6 | 2022 | 126 | 2.080 |
Why?
| Receptors, Progesterone | 24 | 2016 | 326 | 2.040 |
Why?
| Cell Line, Tumor | 36 | 2023 | 2904 | 1.960 |
Why?
| Phenylthiohydantoin | 6 | 2017 | 40 | 1.920 |
Why?
| Receptors, Estrogen | 14 | 2020 | 388 | 1.510 |
Why?
| Tryptophan Oxygenase | 3 | 2018 | 22 | 1.380 |
Why?
| Tryptophan | 2 | 2018 | 140 | 1.240 |
Why?
| Progesterone | 16 | 2014 | 243 | 1.100 |
Why?
| Progestins | 6 | 2014 | 78 | 1.050 |
Why?
| Tamoxifen | 10 | 2016 | 198 | 1.040 |
Why?
| Ovarian Neoplasms | 4 | 2020 | 460 | 1.020 |
Why?
| Ribonuclease III | 2 | 2016 | 38 | 0.940 |
Why?
| Neoplastic Stem Cells | 3 | 2017 | 340 | 0.940 |
Why?
| DEAD-box RNA Helicases | 2 | 2016 | 59 | 0.920 |
Why?
| Epithelial Cells | 3 | 2022 | 995 | 0.920 |
Why?
| Drug Resistance, Neoplasm | 7 | 2020 | 673 | 0.910 |
Why?
| Biomarkers, Tumor | 7 | 2021 | 1076 | 0.900 |
Why?
| Epithelial-Mesenchymal Transition | 5 | 2018 | 182 | 0.900 |
Why?
| Receptor, ErbB-2 | 4 | 2017 | 321 | 0.870 |
Why?
| Cell Proliferation | 14 | 2021 | 2328 | 0.850 |
Why?
| Kallikreins | 1 | 2021 | 33 | 0.830 |
Why?
| Adipokines | 1 | 2021 | 46 | 0.810 |
Why?
| Gene Expression Profiling | 11 | 2018 | 1625 | 0.800 |
Why?
| Neoplasm Recurrence, Local | 6 | 2023 | 903 | 0.800 |
Why?
| Endometrial Neoplasms | 6 | 2011 | 144 | 0.790 |
Why?
| Prostate-Specific Antigen | 1 | 2021 | 160 | 0.770 |
Why?
| Membrane Transport Proteins | 1 | 2021 | 137 | 0.760 |
Why?
| Trophoblasts | 1 | 2022 | 169 | 0.760 |
Why?
| RNA, Long Noncoding | 2 | 2022 | 163 | 0.750 |
Why?
| Immunohistochemistry | 8 | 2017 | 1727 | 0.730 |
Why?
| Androgen Antagonists | 3 | 2017 | 72 | 0.730 |
Why?
| Transcription Factors | 13 | 2023 | 1616 | 0.720 |
Why?
| Transforming Growth Factor beta1 | 1 | 2021 | 169 | 0.720 |
Why?
| Cell Movement | 9 | 2020 | 929 | 0.720 |
Why?
| Pulmonary Alveoli | 1 | 2022 | 395 | 0.720 |
Why?
| Mammary Glands, Animal | 4 | 2022 | 123 | 0.710 |
Why?
| Alternative Splicing | 2 | 2018 | 197 | 0.710 |
Why?
| Homeodomain Proteins | 5 | 2014 | 484 | 0.700 |
Why?
| Repressor Proteins | 6 | 2018 | 384 | 0.700 |
Why?
| Cell Cycle | 4 | 2021 | 584 | 0.680 |
Why?
| RNA Splicing Factors | 1 | 2018 | 51 | 0.650 |
Why?
| Female | 57 | 2023 | 63629 | 0.650 |
Why?
| Mammary Neoplasms, Experimental | 3 | 2017 | 63 | 0.640 |
Why?
| Up-Regulation | 7 | 2020 | 891 | 0.630 |
Why?
| Xenograft Model Antitumor Assays | 8 | 2021 | 747 | 0.610 |
Why?
| Mice | 23 | 2021 | 15888 | 0.610 |
Why?
| Humans | 83 | 2023 | 122796 | 0.600 |
Why?
| Animals | 38 | 2022 | 34133 | 0.600 |
Why?
| Nitriles | 6 | 2017 | 158 | 0.590 |
Why?
| Benzamides | 6 | 2017 | 175 | 0.590 |
Why?
| Carcinoma, Endometrioid | 2 | 2008 | 47 | 0.590 |
Why?
| Lactation | 2 | 2022 | 162 | 0.590 |
Why?
| Gonadal Steroid Hormones | 1 | 2018 | 123 | 0.580 |
Why?
| Lipogenesis | 1 | 2016 | 66 | 0.560 |
Why?
| Paclitaxel | 3 | 2017 | 202 | 0.560 |
Why?
| Antibody Specificity | 1 | 2016 | 190 | 0.560 |
Why?
| Antineoplastic Agents | 6 | 2018 | 1990 | 0.540 |
Why?
| Receptor, trkB | 2 | 2012 | 27 | 0.540 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2015 | 37 | 0.530 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 5 | 0.510 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2017 | 377 | 0.490 |
Why?
| RNA Interference | 3 | 2015 | 473 | 0.480 |
Why?
| Apoptosis | 11 | 2020 | 2532 | 0.480 |
Why?
| Antibodies | 1 | 2016 | 400 | 0.480 |
Why?
| Metformin | 2 | 2014 | 303 | 0.470 |
Why?
| Receptors, Steroid | 2 | 2010 | 54 | 0.470 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2018 | 715 | 0.460 |
Why?
| Kynurenine | 3 | 2018 | 81 | 0.450 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1402 | 0.450 |
Why?
| Chromatin | 1 | 2016 | 450 | 0.440 |
Why?
| Gene Expression Regulation | 8 | 2016 | 2491 | 0.440 |
Why?
| Neoadjuvant Therapy | 2 | 2020 | 348 | 0.430 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2012 | 57 | 0.420 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 46 | 0.420 |
Why?
| Signal Transduction | 17 | 2015 | 4902 | 0.410 |
Why?
| Disease Progression | 6 | 2018 | 2546 | 0.410 |
Why?
| Antineoplastic Agents, Hormonal | 5 | 2020 | 143 | 0.410 |
Why?
| Endometrium | 2 | 2008 | 61 | 0.390 |
Why?
| Transcriptional Activation | 5 | 2017 | 360 | 0.380 |
Why?
| Mice, SCID | 4 | 2020 | 339 | 0.380 |
Why?
| Cell Transformation, Neoplastic | 1 | 2012 | 320 | 0.350 |
Why?
| Tubulin Modulators | 1 | 2009 | 11 | 0.350 |
Why?
| Estradiol | 6 | 2016 | 477 | 0.350 |
Why?
| Cells | 1 | 2009 | 24 | 0.350 |
Why?
| 3' Untranslated Regions | 4 | 2014 | 147 | 0.350 |
Why?
| Neoplasms | 5 | 2022 | 2235 | 0.350 |
Why?
| Uterine Neoplasms | 2 | 2008 | 76 | 0.340 |
Why?
| Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 25 | 0.340 |
Why?
| Cadherins | 4 | 2012 | 190 | 0.340 |
Why?
| Dirofilaria immitis | 3 | 2010 | 3 | 0.320 |
Why?
| Mice, Nude | 5 | 2017 | 668 | 0.310 |
Why?
| Feedback, Physiological | 2 | 2021 | 78 | 0.300 |
Why?
| Trastuzumab | 2 | 2017 | 93 | 0.300 |
Why?
| Cell Nucleus | 5 | 2017 | 598 | 0.290 |
Why?
| Microtubules | 1 | 2009 | 247 | 0.290 |
Why?
| MCF-7 Cells | 3 | 2016 | 115 | 0.290 |
Why?
| Transfection | 5 | 2012 | 909 | 0.290 |
Why?
| Epidermal Growth Factor | 4 | 2005 | 173 | 0.280 |
Why?
| Anilides | 2 | 2016 | 69 | 0.260 |
Why?
| Mice, Inbred NOD | 3 | 2020 | 588 | 0.250 |
Why?
| Cell Differentiation | 1 | 2012 | 1805 | 0.250 |
Why?
| Microarray Analysis | 2 | 2016 | 124 | 0.250 |
Why?
| Down-Regulation | 6 | 2016 | 654 | 0.250 |
Why?
| Lung Neoplasms | 1 | 2017 | 2216 | 0.240 |
Why?
| Gene Expression | 4 | 2020 | 1506 | 0.240 |
Why?
| Molecular Targeted Therapy | 2 | 2018 | 361 | 0.240 |
Why?
| Pharmacology, Clinical | 1 | 2023 | 10 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 783 | 0.230 |
Why?
| Mutation | 5 | 2022 | 3493 | 0.230 |
Why?
| Mammary Glands, Human | 2 | 2014 | 61 | 0.210 |
Why?
| Epigenesis, Genetic | 2 | 2018 | 551 | 0.210 |
Why?
| Neoplasm Invasiveness | 3 | 2015 | 472 | 0.210 |
Why?
| Tumor Cells, Cultured | 11 | 2020 | 904 | 0.210 |
Why?
| Milk Proteins | 2 | 1999 | 39 | 0.210 |
Why?
| NF-E2-Related Factor 2 | 1 | 2022 | 84 | 0.210 |
Why?
| Estrogens | 3 | 2020 | 325 | 0.200 |
Why?
| Epithelium | 1 | 2022 | 309 | 0.200 |
Why?
| Neoplastic Cells, Circulating | 1 | 2022 | 64 | 0.200 |
Why?
| Mice, Transgenic | 2 | 2017 | 2079 | 0.200 |
Why?
| Neoplasms, Second Primary | 1 | 2022 | 91 | 0.200 |
Why?
| Tumor Microenvironment | 2 | 2022 | 457 | 0.200 |
Why?
| Promoter Regions, Genetic | 6 | 2014 | 1188 | 0.200 |
Why?
| Semaphorins | 1 | 2020 | 23 | 0.190 |
Why?
| DNA-Binding Proteins | 6 | 2018 | 1384 | 0.190 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2020 | 40 | 0.190 |
Why?
| Neoplasm Proteins | 2 | 2018 | 415 | 0.190 |
Why?
| Respiratory Mucosa | 1 | 2022 | 263 | 0.190 |
Why?
| Epoxy Compounds | 1 | 2020 | 34 | 0.180 |
Why?
| NF-kappa B | 2 | 2015 | 676 | 0.180 |
Why?
| Immune Tolerance | 1 | 2022 | 355 | 0.180 |
Why?
| Androgens | 1 | 2021 | 169 | 0.180 |
Why?
| Transcription, Genetic | 9 | 2012 | 1355 | 0.180 |
Why?
| Gene Knockdown Techniques | 2 | 2020 | 322 | 0.180 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2020 | 48 | 0.180 |
Why?
| STAT5 Transcription Factor | 3 | 2014 | 44 | 0.180 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2020 | 54 | 0.180 |
Why?
| Pregnancy | 3 | 2022 | 5854 | 0.180 |
Why?
| RNA, Messenger | 7 | 2011 | 2720 | 0.180 |
Why?
| Chemotherapy, Adjuvant | 1 | 2020 | 369 | 0.170 |
Why?
| Prolactin | 1 | 1998 | 97 | 0.170 |
Why?
| Gene Amplification | 1 | 2018 | 98 | 0.160 |
Why?
| RNA, Small Interfering | 3 | 2020 | 581 | 0.160 |
Why?
| Antigens, CD | 1 | 2020 | 506 | 0.160 |
Why?
| Immunoblotting | 3 | 2010 | 318 | 0.160 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 115 | 0.160 |
Why?
| Endometrial Hyperplasia | 2 | 2008 | 16 | 0.160 |
Why?
| Binding Sites | 5 | 2016 | 1247 | 0.150 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 2017 | 41 | 0.150 |
Why?
| Everolimus | 1 | 2017 | 64 | 0.150 |
Why?
| Histone Acetyltransferases | 3 | 2006 | 53 | 0.150 |
Why?
| Fatty Acids | 1 | 2020 | 410 | 0.150 |
Why?
| Dihydrotestosterone | 1 | 2017 | 39 | 0.150 |
Why?
| Cluster Analysis | 4 | 2008 | 493 | 0.150 |
Why?
| Estrogen Receptor Modulators | 3 | 2008 | 19 | 0.150 |
Why?
| Immunity, Cellular | 1 | 2018 | 276 | 0.150 |
Why?
| Neoplasm Transplantation | 2 | 2014 | 248 | 0.150 |
Why?
| Cyclohexanes | 1 | 2016 | 20 | 0.150 |
Why?
| Heterografts | 1 | 2017 | 132 | 0.150 |
Why?
| Tumor Suppressor Proteins | 2 | 2014 | 299 | 0.140 |
Why?
| Carcinogenesis | 1 | 2018 | 184 | 0.140 |
Why?
| Placenta | 1 | 2022 | 648 | 0.140 |
Why?
| Hyaluronan Receptors | 2 | 2014 | 96 | 0.140 |
Why?
| Trans-Activators | 4 | 2006 | 382 | 0.140 |
Why?
| Killer Cells, Natural | 1 | 2018 | 386 | 0.140 |
Why?
| Ovary | 1 | 2017 | 209 | 0.140 |
Why?
| Transplantation, Heterologous | 2 | 2014 | 194 | 0.130 |
Why?
| Phosphoproteins | 2 | 2008 | 332 | 0.130 |
Why?
| Neoplasm Metastasis | 2 | 2015 | 563 | 0.130 |
Why?
| Hormones | 1 | 2015 | 136 | 0.130 |
Why?
| Drug Delivery Systems | 1 | 2017 | 312 | 0.130 |
Why?
| Tosyl Compounds | 1 | 2014 | 14 | 0.120 |
Why?
| Sarcoma, Ewing | 1 | 2015 | 66 | 0.120 |
Why?
| Genes, Reporter | 2 | 2012 | 274 | 0.120 |
Why?
| Ligands | 6 | 2023 | 582 | 0.120 |
Why?
| Protein Transport | 1 | 2015 | 418 | 0.120 |
Why?
| HEK293 Cells | 1 | 2016 | 651 | 0.120 |
Why?
| PTEN Phosphohydrolase | 1 | 2015 | 149 | 0.120 |
Why?
| Disease Models, Animal | 2 | 2021 | 3799 | 0.120 |
Why?
| In Situ Hybridization | 2 | 2010 | 324 | 0.120 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 1993 | 51 | 0.110 |
Why?
| Cellular Reprogramming | 1 | 2014 | 88 | 0.110 |
Why?
| Ketones | 1 | 1993 | 45 | 0.110 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 985 | 0.110 |
Why?
| Cell Adhesion | 2 | 2012 | 454 | 0.110 |
Why?
| Neurotrophin 3 | 1 | 2012 | 16 | 0.110 |
Why?
| Autocrine Communication | 1 | 2012 | 43 | 0.110 |
Why?
| Cells, Cultured | 2 | 2016 | 4162 | 0.110 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 358 | 0.110 |
Why?
| Aromatase Inhibitors | 2 | 2014 | 52 | 0.110 |
Why?
| Metalloendopeptidases | 1 | 1992 | 57 | 0.110 |
Why?
| Cysteine Endopeptidases | 1 | 1992 | 61 | 0.110 |
Why?
| Mice, Inbred C57BL | 2 | 2016 | 5020 | 0.110 |
Why?
| Nuclear Proteins | 5 | 2000 | 618 | 0.110 |
Why?
| Transduction, Genetic | 1 | 2012 | 118 | 0.110 |
Why?
| Disease-Free Survival | 1 | 2014 | 661 | 0.110 |
Why?
| Gene Silencing | 2 | 2014 | 178 | 0.110 |
Why?
| Middle Aged | 6 | 2016 | 28563 | 0.100 |
Why?
| Tubulin | 1 | 2012 | 126 | 0.100 |
Why?
| Luciferases | 1 | 2012 | 150 | 0.100 |
Why?
| Tumor Burden | 1 | 2012 | 277 | 0.100 |
Why?
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 5 | 0.100 |
Why?
| Carrier Proteins | 2 | 2023 | 740 | 0.100 |
Why?
| Receptors, Leptin | 1 | 2011 | 28 | 0.100 |
Why?
| Tissue Array Analysis | 2 | 2008 | 58 | 0.100 |
Why?
| Protein Biosynthesis | 2 | 2012 | 408 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2016 | 1947 | 0.100 |
Why?
| GTPase-Activating Proteins | 1 | 2011 | 75 | 0.100 |
Why?
| Fibronectins | 1 | 2011 | 115 | 0.090 |
Why?
| Microfilament Proteins | 1 | 2011 | 135 | 0.090 |
Why?
| Cell Transdifferentiation | 1 | 2010 | 32 | 0.090 |
Why?
| Retinoid X Receptors | 1 | 2010 | 38 | 0.090 |
Why?
| HeLa Cells | 5 | 2006 | 609 | 0.090 |
Why?
| Enzyme Inhibitors | 2 | 2008 | 836 | 0.090 |
Why?
| Cyclins | 3 | 1999 | 82 | 0.090 |
Why?
| Protein Isoforms | 4 | 2006 | 347 | 0.090 |
Why?
| Breast | 2 | 2022 | 141 | 0.090 |
Why?
| DNA, Complementary | 4 | 2008 | 270 | 0.090 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2010 | 346 | 0.090 |
Why?
| Inflammation | 1 | 2020 | 2598 | 0.090 |
Why?
| Lung | 1 | 2022 | 3830 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 1003 | 0.090 |
Why?
| Cell Line, Transformed | 1 | 2009 | 140 | 0.090 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 196 | 0.080 |
Why?
| Perilipin-1 | 1 | 2008 | 16 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2016 | 2977 | 0.080 |
Why?
| S100 Proteins | 1 | 2008 | 35 | 0.080 |
Why?
| Leiomyoma | 1 | 2008 | 46 | 0.080 |
Why?
| Glucose | 1 | 2013 | 968 | 0.080 |
Why?
| Drug Interactions | 1 | 2009 | 356 | 0.080 |
Why?
| Hysterectomy | 1 | 2008 | 119 | 0.080 |
Why?
| Receptor, IGF Type 1 | 1 | 2006 | 59 | 0.070 |
Why?
| Survival Rate | 2 | 2020 | 1810 | 0.070 |
Why?
| Aged | 4 | 2016 | 20495 | 0.070 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 1055 | 0.070 |
Why?
| Stem Cells | 1 | 2010 | 576 | 0.070 |
Why?
| Molecular Sequence Data | 6 | 2010 | 2933 | 0.070 |
Why?
| Precancerous Conditions | 1 | 2006 | 164 | 0.060 |
Why?
| Thromboplastin | 1 | 2004 | 73 | 0.060 |
Why?
| Neoplasm Staging | 1 | 2008 | 1234 | 0.060 |
Why?
| Protein Binding | 4 | 2010 | 2010 | 0.060 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 114 | 0.060 |
Why?
| Obesity | 1 | 2017 | 2786 | 0.060 |
Why?
| Ovariectomy | 2 | 2017 | 125 | 0.060 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 432 | 0.060 |
Why?
| Postmenopause | 3 | 2017 | 307 | 0.060 |
Why?
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 32 | 0.060 |
Why?
| Amino Acid Sequence | 4 | 2010 | 2123 | 0.060 |
Why?
| Adult | 4 | 2016 | 32385 | 0.050 |
Why?
| Immune Evasion | 1 | 2022 | 48 | 0.050 |
Why?
| Prognosis | 2 | 2020 | 3563 | 0.050 |
Why?
| ErbB Receptors | 1 | 2005 | 571 | 0.050 |
Why?
| Fibroblasts | 1 | 2006 | 846 | 0.050 |
Why?
| Larva | 2 | 1993 | 223 | 0.050 |
Why?
| Promegestone | 4 | 2005 | 33 | 0.050 |
Why?
| Biology | 1 | 2022 | 87 | 0.050 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 178 | 0.050 |
Why?
| Mifepristone | 2 | 2000 | 66 | 0.050 |
Why?
| Drug Resistance | 2 | 2000 | 169 | 0.050 |
Why?
| Treatment Outcome | 1 | 2015 | 9692 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2004 | 537 | 0.050 |
Why?
| GPI-Linked Proteins | 1 | 2020 | 57 | 0.050 |
Why?
| Mammals | 1 | 2022 | 257 | 0.050 |
Why?
| Exons | 2 | 1999 | 310 | 0.050 |
Why?
| Young Adult | 1 | 2016 | 11094 | 0.050 |
Why?
| Antigens, Nuclear | 1 | 2000 | 19 | 0.050 |
Why?
| Postpartum Period | 1 | 2022 | 281 | 0.050 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 88 | 0.050 |
Why?
| Adenocarcinoma | 1 | 2006 | 837 | 0.040 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1999 | 64 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2008 | 6845 | 0.040 |
Why?
| Receptor Cross-Talk | 1 | 1998 | 23 | 0.040 |
Why?
| p300-CBP Transcription Factors | 1 | 2018 | 16 | 0.040 |
Why?
| Immunological Synapses | 1 | 2018 | 18 | 0.040 |
Why?
| DNA Helicases | 1 | 2000 | 136 | 0.040 |
Why?
| STAT1 Transcription Factor | 1 | 1998 | 68 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 177 | 0.040 |
Why?
| Drug Synergism | 1 | 1998 | 346 | 0.040 |
Why?
| Oxygenases | 1 | 1997 | 10 | 0.040 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 1998 | 196 | 0.040 |
Why?
| Receptor, ErbB-3 | 1 | 2017 | 42 | 0.040 |
Why?
| Biological Transport | 1 | 1998 | 392 | 0.040 |
Why?
| Cell Culture Techniques | 1 | 2020 | 354 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2020 | 1174 | 0.040 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 1998 | 306 | 0.040 |
Why?
| Ribosomal Proteins | 1 | 1997 | 68 | 0.040 |
Why?
| Carcinogens | 1 | 1997 | 110 | 0.040 |
Why?
| STAT3 Transcription Factor | 1 | 1998 | 193 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2020 | 931 | 0.040 |
Why?
| Steroids | 1 | 2017 | 156 | 0.040 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 354 | 0.040 |
Why?
| Analysis of Variance | 2 | 2005 | 1329 | 0.040 |
Why?
| Sequence Alignment | 2 | 2010 | 343 | 0.040 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 294 | 0.040 |
Why?
| Muscle, Smooth, Vascular | 1 | 1999 | 454 | 0.040 |
Why?
| Male | 2 | 2021 | 59639 | 0.030 |
Why?
| Histones | 2 | 2014 | 562 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 356 | 0.030 |
Why?
| Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 16 | 0.030 |
Why?
| Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 16 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2017 | 1245 | 0.030 |
Why?
| Keratin-5 | 1 | 2014 | 47 | 0.030 |
Why?
| Base Sequence | 3 | 2008 | 2186 | 0.030 |
Why?
| Nuclear Receptor Coactivator 1 | 2 | 2006 | 10 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2017 | 686 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 353 | 0.030 |
Why?
| Genetic Variation | 1 | 1999 | 952 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 702 | 0.030 |
Why?
| Dipeptides | 1 | 1993 | 50 | 0.030 |
Why?
| Adipose Tissue | 1 | 2017 | 616 | 0.030 |
Why?
| DNA Primers | 2 | 2008 | 540 | 0.030 |
Why?
| Chromatography | 1 | 1992 | 26 | 0.030 |
Why?
| Microscopy, Electron | 1 | 1993 | 418 | 0.030 |
Why?
| Elastin | 1 | 1992 | 78 | 0.030 |
Why?
| Hydrolysis | 1 | 1992 | 189 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1992 | 106 | 0.030 |
Why?
| Follow-Up Studies | 1 | 2020 | 4768 | 0.020 |
Why?
| Blotting, Northern | 1 | 2010 | 199 | 0.020 |
Why?
| Cell Size | 1 | 2010 | 86 | 0.020 |
Why?
| Glycoproteins | 1 | 1992 | 323 | 0.020 |
Why?
| Oligopeptides | 1 | 1992 | 255 | 0.020 |
Why?
| Cell Dedifferentiation | 1 | 2010 | 30 | 0.020 |
Why?
| DNA, Helminth | 1 | 2010 | 16 | 0.020 |
Why?
| COS Cells | 2 | 2003 | 187 | 0.020 |
Why?
| Collagen | 1 | 1992 | 436 | 0.020 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 77 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2010 | 141 | 0.020 |
Why?
| DNA Methylation | 1 | 2014 | 511 | 0.020 |
Why?
| Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.020 |
Why?
| Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| Extracellular Matrix | 1 | 1992 | 461 | 0.020 |
Why?
| Rats | 1 | 2017 | 5426 | 0.020 |
Why?
| Phosphorylation | 2 | 2005 | 1733 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2008 | 79 | 0.020 |
Why?
| Myometrium | 1 | 2008 | 35 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 2 | 2005 | 1981 | 0.020 |
Why?
| Cell Division | 2 | 2000 | 788 | 0.020 |
Why?
| DNA, Neoplasm | 1 | 2008 | 155 | 0.020 |
Why?
| Androstadienes | 1 | 2008 | 95 | 0.020 |
Why?
| Trypan Blue | 1 | 2006 | 4 | 0.020 |
Why?
| Comet Assay | 1 | 2006 | 17 | 0.020 |
Why?
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 6 | 0.020 |
Why?
| Sequence Analysis, DNA | 1 | 2010 | 766 | 0.020 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2006 | 59 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3662 | 0.020 |
Why?
| Insulin Receptor Substrate Proteins | 1 | 2006 | 59 | 0.020 |
Why?
| Radiation, Ionizing | 1 | 2006 | 74 | 0.020 |
Why?
| Staining and Labeling | 1 | 2006 | 159 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2006 | 140 | 0.020 |
Why?
| Mutant Proteins | 1 | 2006 | 101 | 0.020 |
Why?
| Androstenes | 1 | 2005 | 11 | 0.020 |
Why?
| Amino Acid Motifs | 1 | 2006 | 206 | 0.020 |
Why?
| Neuroblastoma | 1 | 2006 | 137 | 0.020 |
Why?
| Recombinant Fusion Proteins | 2 | 2000 | 661 | 0.020 |
Why?
| Medroxyprogesterone Acetate | 1 | 2005 | 30 | 0.020 |
Why?
| Caspase 3 | 1 | 2006 | 246 | 0.020 |
Why?
| Levonorgestrel | 1 | 2005 | 31 | 0.020 |
Why?
| Desogestrel | 1 | 2005 | 42 | 0.020 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 341 | 0.020 |
Why?
| DNA Repair | 1 | 2006 | 203 | 0.020 |
Why?
| Alkaline Phosphatase | 1 | 2005 | 161 | 0.020 |
Why?
| Insulin-Like Growth Factor I | 1 | 2006 | 288 | 0.020 |
Why?
| Sucrose | 1 | 2004 | 105 | 0.020 |
Why?
| Adenosine Triphosphate | 1 | 2006 | 456 | 0.020 |
Why?
| DNA Damage | 1 | 2006 | 368 | 0.020 |
Why?
| Reactive Oxygen Species | 1 | 2006 | 592 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2006 | 832 | 0.010 |
Why?
| Microscopy, Confocal | 1 | 2004 | 319 | 0.010 |
Why?
| Mutagenesis | 1 | 2003 | 185 | 0.010 |
Why?
| Progesterone Congeners | 1 | 2002 | 15 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 2003 | 376 | 0.010 |
Why?
| Uterus | 1 | 2003 | 197 | 0.010 |
Why?
| Dimerization | 1 | 2002 | 184 | 0.010 |
Why?
| Cell Survival | 1 | 2004 | 1075 | 0.010 |
Why?
| Plasmids | 1 | 2002 | 358 | 0.010 |
Why?
| DNA-Activated Protein Kinase | 1 | 2000 | 11 | 0.010 |
Why?
| Ku Autoantigen | 1 | 2000 | 12 | 0.010 |
Why?
| Glutathione Transferase | 1 | 2000 | 98 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 2006 | 1306 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2003 | 1318 | 0.010 |
Why?
| Culture Techniques | 1 | 1999 | 81 | 0.010 |
Why?
| Methionine | 1 | 2000 | 147 | 0.010 |
Why?
| Growth Substances | 1 | 1999 | 140 | 0.010 |
Why?
| Cricetinae | 1 | 1999 | 269 | 0.010 |
Why?
| Estrogen Receptor beta | 1 | 1999 | 36 | 0.010 |
Why?
| RNA | 1 | 2005 | 854 | 0.010 |
Why?
| Phosphotyrosine | 1 | 1998 | 47 | 0.010 |
Why?
| Receptors, Growth Factor | 1 | 1998 | 51 | 0.010 |
Why?
| Peptide Fragments | 1 | 2003 | 715 | 0.010 |
Why?
| Premenopause | 1 | 1999 | 109 | 0.010 |
Why?
| Sp1 Transcription Factor | 1 | 1998 | 23 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 156 | 0.010 |
Why?
| Estrogen Antagonists | 1 | 1998 | 39 | 0.010 |
Why?
| Chromosome Mapping | 1 | 1999 | 518 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 159 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 179 | 0.010 |
Why?
| Isomerism | 1 | 1997 | 43 | 0.010 |
Why?
| Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 290 | 0.010 |
Why?
| Gene Deletion | 1 | 1999 | 365 | 0.010 |
Why?
| Yeasts | 1 | 1997 | 52 | 0.010 |
Why?
| Autoantigens | 1 | 2000 | 407 | 0.010 |
Why?
| Blotting, Western | 1 | 1998 | 1225 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 1998 | 1021 | 0.010 |
Why?
| Time Factors | 1 | 2004 | 6682 | 0.010 |
Why?
| Cell Line | 1 | 1998 | 2785 | 0.010 |
Why?
| Cytokines | 1 | 1999 | 1928 | 0.010 |
Why?
| Models, Biological | 1 | 1998 | 1756 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|